Last $0.32 USD
Change Today -0.024 / -6.98%
Volume 2.0M
BCLI On Other Exchanges
Symbol
Exchange
OTC BB
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

brainstorm cell therapeutics (BCLI) Snapshot

Open
$0.34
Previous Close
$0.34
Day High
$0.35
Day Low
$0.32
52 Week High
07/8/14 - $0.38
52 Week Low
12/9/13 - $0.10
Market Cap
72.7M
Average Volume 10 Days
649.4K
EPS TTM
--
Shares Outstanding
227.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BRAINSTORM CELL THERAPEUTICS (BCLI)

brainstorm cell therapeutics (BCLI) Related Bloomberg News

View More Bloomberg News

brainstorm cell therapeutics (BCLI) Related Businessweek News

No Related Businessweek News Found

brainstorm cell therapeutics (BCLI) Details

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics was founded in 2000 and is based in New York, New York.

14 Employees
Last Reported Date: 03/28/14
Founded in 2000

brainstorm cell therapeutics (BCLI) Top Compensated Officers

President
Total Annual Compensation: --
Chief Financial Officer and Principal Account...
Total Annual Compensation: $106.0K
Compensation as of Fiscal Year 2013.

brainstorm cell therapeutics (BCLI) Key Developments

Brainstorm Cell Therapeutics Inc. Proposes Amendments to Certificate of Incorporation

Brainstorm Cell Therapeutics Inc. at the Annual Meeting of stockholders to be held on August 14, 2014, proposed amendments to the company’s Certificate of Incorporation to effect a reverse stock split of the company’s issued and outstanding shares of Common Stock by a ratio of between 1-for-10 and 1-for-20, inclusive.

Brainstorm Cell Therapeutics Inc. Announces Publication of Preclinical Multidose Study of NurOwn

Brainstorm Cell Therapeutics Inc. announced publication of an important preclinical study in the journal Clinical and Translational Medicine. This paper describes the safety of single and repeated intramuscular administration of NurOwn, the Company's proprietary mesenchymal stem cells that are induced to secrete a variety of neurotrophic factors. NurOwn is in clinical development for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and has demonstrated efficacy in preclinical models of a variety of neurodegenerative diseases, including Parkinson's disease, Huntingon's disease and multiple sclerosis. The results published are important because they establish that repeated doses of NurOwn are safe in mice and more specifically, that mice generate only minimal immune response after repeated exposure to NurOwn, which are human cells. These data will help support the use of multiple doses of NurOwn in future clinical trials. One of the major goals of this study was to determine if normal mice develop an immune response to NurOwn after repeated exposures to the cells. The study assessed a variety of Th1 and Th2 cytokines in these mice, which have a normally functioning immune system, and observed only transient increases in interleukin (IL)-5, IL-6 and to a lesser extent IL-2, which returned to baseline within 24 hours after administration of NurOwn. Importantly, IL-4 and IL-10, which are key regulators of the humoral immune response, were undetectable before and after treatment. Thus, there was no substantial or durable immune response to NurOwn after two or three repeated administrations in mice, despite the fact that the cells were of human origin. In addition, the repeated administration of NurOwn was well-tolerated in these mice, with no evidence of systemic toxicity and minor irritation seen at the site of intramuscular administration.

Brainstorm Cell Therapeutics Inc. Appoints Uri Yablonka as Chief Operating Officer and Member of the Board

On June 6, 2014, Brainstorm Cell Therapeutics Inc. appointed Uri Yablonka as Chief Operating Officer, effective June 6, 2014. Prior to joining the company and the subsidiary, Mr. Yablonka served since 2011as owner and General Manager of Uri Yablonka Ltd. He also served since 2011 as Vice President, Business Development at ACC International Holdings Ltd. Effective June 6, 2014, the Board elected Uri Yablonka to serve as a member of the Board and increased the size of the Board accordingly.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCLI:US $0.32 USD -0.024

BCLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BCLI.
View Industry Companies
 

Industry Analysis

BCLI

Industry Average

Valuation BCLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 65.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRAINSTORM CELL THERAPEUTICS, please visit www.brainstorm-cell.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.